Citizens Financial Group Inc. RI Makes New $683,000 Investment in Medpace Holdings, Inc. $MEDP

Citizens Financial Group Inc. RI bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,289 shares of the company’s stock, valued at approximately $683,000.

Several other hedge funds have also modified their holdings of the stock. California State Teachers Retirement System boosted its position in Medpace by 22.1% in the 1st quarter. California State Teachers Retirement System now owns 26,042 shares of the company’s stock valued at $12,505,000 after buying an additional 4,719 shares during the last quarter. Cerity Partners LLC raised its position in shares of Medpace by 41.0% during the fourth quarter. Cerity Partners LLC now owns 80,973 shares of the company’s stock worth $45,478,000 after acquiring an additional 23,530 shares during the last quarter. Focus Partners Advisor Solutions LLC bought a new stake in shares of Medpace during the second quarter worth $1,685,000. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Medpace by 24,930.4% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 101,373 shares of the company’s stock valued at $56,936,000 after acquiring an additional 100,968 shares during the period. Finally, Mitchell Capital Management Co. bought a new position in Medpace in the fourth quarter valued at about $3,383,000. 77.98% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Medpace news, VP Susan E. Burwig sold 7,500 shares of the business’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total value of $4,500,000.00. Following the completion of the transaction, the vice president directly owned 62,984 shares of the company’s stock, valued at approximately $37,790,400. The trade was a 10.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Cornelius P. Mccarthy III sold 1,140 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $605.37, for a total value of $690,121.80. Following the completion of the sale, the director owned 12,275 shares of the company’s stock, valued at $7,430,916.75. This trade represents a 8.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 67,195 shares of company stock valued at $37,989,998. Insiders own 20.50% of the company’s stock.

Medpace Stock Up 3.0%

Shares of NASDAQ MEDP opened at $608.27 on Thursday. The company’s fifty day moving average is $544.34 and its 200-day moving average is $491.59. The stock has a market cap of $16.98 billion, a price-to-earnings ratio of 35.65, a P/E/G ratio of 2.63 and a beta of 1.15. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter in the prior year, the company earned $3.10 EPS. The firm’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MEDP has been the subject of a number of research reports. Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. Barclays set a $600.00 target price on shares of Medpace in a research report on Thursday, July 23rd. Royal Bank Of Canada raised their target price on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and lifted their price target for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. Finally, Robert W. Baird boosted their price target on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $584.18.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.